2,537 Shares in Glaukos Co. (NYSE:GKOS) Acquired by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP purchased a new stake in Glaukos Co. (NYSE:GKOS) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 2,537 shares of the medical instruments supplier’s stock, valued at approximately $331,000.

A number of other large investors also recently made changes to their positions in the business. EFG Asset Management North America Corp. boosted its position in shares of Glaukos by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier’s stock worth $3,216,000 after acquiring an additional 128 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Glaukos in the 3rd quarter valued at $25,000. New York State Teachers Retirement System grew its stake in shares of Glaukos by 0.4% during the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier’s stock valued at $6,272,000 after buying an additional 200 shares during the period. KBC Group NV grew its stake in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 201 shares during the period. Finally, Inspire Investing LLC raised its position in shares of Glaukos by 6.9% in the 3rd quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier’s stock worth $416,000 after buying an additional 206 shares during the period. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on GKOS. StockNews.com raised Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. BTIG Research increased their target price on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Piper Sandler set a $140.00 price objective on shares of Glaukos in a research note on Thursday, October 17th. Needham & Company LLC raised their target price on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, JPMorgan Chase & Co. upped their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $134.55.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at $14,198,425.93. The trade was a 2.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gilbert H. Kliman sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at approximately $4,225,345.12. The trade was a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

Shares of GKOS opened at $142.88 on Tuesday. The firm has a market cap of $7.88 billion, a price-to-earnings ratio of -47.31 and a beta of 1.02. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $132.40 and its two-hundred day moving average is $123.80. Glaukos Co. has a 52-week low of $59.22 and a 52-week high of $146.86.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.20. The firm had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm’s quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.50) earnings per share. Analysts forecast that Glaukos Co. will post -1.96 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.